antibodies, ChAdOx1 nCoV-19, COVID-19, Covid-19 vaccines, Dublin, EU, Ireland, Jenner Institute, killer T-cells, Oxford COVID Vaccine Trial Group, Oxford vaccine, Professor A.V.S. Hill, Professor Pollard, Safety, Sarah Gilbert, T-cells, T. Lambe, UK, vaccine, vaccine trials, Vaccines
Monkeys did well even when exposed to Covid-19 in large amounts. Human trials look promising. Professor Sarah Gilbert, project lead, gave the vaccine to her 21 year old triplets, who are biochemists. So, she seems to believe in her vaccine. We are vaccine skeptics and Oxford skeptics, but this looks hopeful. 🍀 For this vaccine, the research apparently came first and then a pharma company was sought, and not vice versa.
Link “Oxford’s scientists explain the Phase I/II results for the COVID-19 vaccine“: https://youtu.be/HiLdEaSOJN4
This excerpt is very important as some vaccines for SARS-CoV (this is SARS-CoV-2) made the disease worse:
“In rhesus macaques, a single vaccination with ChAdOx1 nCoV-19 induced humoral and cellular immune responses. Protection against lower respiratory tract infection was observed in vaccinated non-human primates after high-dose SARS-CoV-2 challenge” Rhesus macaques are monkeys; “challenge” means that they were exposed (to high doses) of Covid-19. A chimp cold virus (chimp adenovirus) is used as a sort of carrier, rather than a human cold virus, as in some proposed Covid-19 vaccines.
“Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”
Pedro M Folegatti*, Katie J Ewer*, Parvinder K Aley, Brian Angus, Stephan Becker, Sandra Belij-Rammerstorfer, Duncan Bellamy, Sagida Bibi, Mustapha Bittaye, Elizabeth A Clutterbuck, Christina Dold, Saul N Faust, Adam Finn, Amy L Flaxman, Bassam Hallis, Paul Heath, Daniel Jenkin, Rajeka Lazarus, Rebecca Makinson, Angela M Minassian, Katrina M Pollock, Maheshi Ramasamy, Hannah Robinson, Matthew Snape, Richard Tarrant, Merryn Voysey, Catherine Green*, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard*, on behalf of the Oxford COVID Vaccine Trial Group†